Patient Inquiry  |  For the Media  |  

 

ALS Clinical

Approved for sale in Europe, CE Registration #518356 .

"US Investigational Device, not currently available for sale in the US .

Initial study of the device in ALS provided the feasibility of using diaphragmic pacing to slow the decline in a patient's Forced Vital Capacity and delay the onset of respiratory failure. Data from our pilot study revealed the average pre-implant rate of decline was calculated at -2.8% per month and for patients with at least 9 months post-implant follow-up the rate improved to
-1.0% per month.

We are also investigating to determine if the NeuRx DPS™ may be effective in ventilatory support of patients with ALS either decreasing or eliminating the need for negative or positive pressure mechanical ventilation.

Download the ALS Patient/Caregiver Brochure [PDF]

View ALS Patient/Caregiver Video

Or for information about the open ALS clinical trial please contact: